China CAS:28721-07-5 Manufacturer

We not only will try our greatest to offer superb companies to just about every buyer, but also are ready to receive any suggestion offered by our shoppers for CAS:28721-07-5, We are going to do our best to fulfill your specifications and are sincerely searching forward to building mutual valuable organization romantic relationship along with you!
CAS:28721-07-5, Welcome to visit our company and factory, there are various solutions displayed in our showroom that will meet your expectation, meanwhile, if you are convenient to visit our website, our sales staff will try their efforts to deliver you the best service

Hot Products

  • Estradiol Hemihydrate

    Estradiol Hemihydrate

    Estradiol Hemihydrate has USP and EP specification. DMF available.

    CAS:50-28-2

  • N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide

    N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide

    N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide is an intermediate of Dutasteride.

    CAS:98319-24-5

  • Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets Specifications:50mg*24
    Indications:Anti-androgen
  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • Fluticasone Furoate

    Fluticasone Furoate

    Fluticasone furoate has In-house specifications. DMF under filing.

    CAS:397864-44-7

  • Mifepristone Tablets

    Mifepristone Tablets

    Mifepristone Tablets Specifications:10mg*1
    Indications:Emergency Contraceptive

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept